Chaliponga

Chaliponga leaves contain N,N-dimethyltryptamine (DMT) at concentrations of 0.17–1.75% dry weight, which acts as a potent agonist at serotonin 5-HT2A receptors to produce profound hallucinogenic effects when orally bioavailable through MAO inhibition. In vitro studies document aqueous extract inhibition of α-glucosidase (IC50 = 4.78 µg/mL) and 5-lipoxygenase (IC50 = 79.77 µg/mL), suggesting antidiabetic and anti-inflammatory potential, though no clinical trials have isolated these effects in humans.

Origin & History

Diplopterys cabrerana is a woody liana native to the Amazon basin, distributed across Ecuador, Colombia, Peru, and Brazil, where it thrives in humid tropical rainforest understory environments at low to mid elevations. It is not widely cultivated commercially and is harvested predominantly from wild populations by indigenous communities for ceremonial use. The vine is closely associated with riparian zones and secondary forest margins across western Amazonia, where it has been integrated into indigenous botanical knowledge for centuries.

Historical & Cultural Context

Diplopterys cabrerana has been used for centuries by indigenous Amazonian peoples including Shuar, Cofán, Siona, and related groups of Ecuador, Colombia, and adjacent territories, where it is known regionally as Chaliponga, Chagropanga, or Biaxii, and serves as a primary DMT-contributing admixture to ayahuasca brews used for healing ceremonies, divination, and spiritual communication. Unlike Psychotria viridis (Chacruna), which predominates in Peruvian ayahuasca traditions, D. cabrerana is more characteristic of northwestern Amazonian and upper Orinoco ethnobotanical traditions, representing distinct regional shamanic lineages with their own ritual protocols and cosmological frameworks. Traditional preparation involves prolonged boiling of the vine leaves alongside Banisteriopsis caapi, with ceremonial intent, dietary restriction (the traditional dieta), and ritual context considered integral to efficacy and safety within indigenous systems. In the late 20th and early 21st centuries, global interest in ayahuasca tourism and psychedelic-assisted therapy has introduced D. cabrerana to Western awareness, though its use outside of traditional contexts raises significant cultural, legal, and safety concerns.

Health Benefits

- **Entheogenic and Psychoactive Activity**: DMT at 0.17–1.75% dry weight engages 5-HT2A serotonin receptors with high affinity, producing visionary states; oral activity requires co-administration with MAO inhibitors such as β-carbolines from Banisteriopsis caapi.
- **Anti-inflammatory Potential**: Aqueous extracts inhibit 5-lipoxygenase with an IC50 of 79.77 µg/mL in vitro, suggesting suppression of leukotriene biosynthesis; apigenin derivatives identified in the extract may contribute to this effect through NF-κB pathway modulation.
- **Antidiabetic Potential**: Aqueous leaf extracts demonstrate α-glucosidase inhibition with an IC50 of 4.78 µg/mL in vitro, a potency comparable to some pharmaceutical leads; this postprandial glucose-modulating effect has not been validated in animal or human studies.
- **Antioxidant Activity**: Extracts exhibit nitric oxide scavenging capacity at concentrations above 1.953 µg/mL and xanthine oxidase inhibition above 31.25 µg/mL, activities likely attributable to catechin and apigenin derivatives identified in phytochemical profiling.
- **Neuroprotective Observations (Preclinical)**: No cytotoxicity was observed in human neuroblastoma SH-SY5Y cells at concentrations up to 1000 µg/mL of aqueous extract, suggesting a favorable neuronal safety margin at studied concentrations, though functional neuroprotection assays have not been conducted.
- **Acetylcholinesterase Inhibition**: Aqueous extracts inhibit acetylcholinesterase activity beginning at 250 µg/mL in vitro, implying a potential cholinergic-enhancing effect relevant to cognition and memory, though this has not been explored in any in vivo model.
- **Ritualistic and Psychospiritual Benefit (Traditional Context)**: Within Amazonian indigenous frameworks, ceremonial use is associated with healing, visionary diagnosis, and psychological integration; emerging psychedelic-assisted therapy research on ayahuasca brews (containing D. cabrerana as admixture) suggests potential for mood and trauma-related applications.

How It Works

The primary psychoactive mechanism centers on DMT's high-affinity agonism at serotonin 5-HT2A receptors in the cortex and limbic system, producing glutamate release, altered thalamo-cortical gating, and hallucinogenic perception; DMT also interacts with sigma-1 receptors and trace amine-associated receptors (TAARs), which may modulate neuroprotective and immunomodulatory signaling. Following oral ingestion, DMT is rapidly metabolized by monoamine oxidase A in the gut wall and liver, rendering it orally inactive without co-administered MAO inhibitors such as harmine and harmaline from Banisteriopsis caapi, which reversibly inhibit MAO-A and allow systemic DMT absorption. Beyond psychoactive alkaloids, aqueous extract constituents including catechins and apigenin derivatives contribute to anti-inflammatory effects via inhibition of 5-lipoxygenase (blocking leukotriene synthesis) and suppression of nitric oxide overproduction, while α-glucosidase inhibition at the intestinal brush border would theoretically delay carbohydrate digestion and attenuate postprandial glucose spikes. Acetylcholinesterase inhibition by unidentified polar constituents at 250 µg/mL suggests augmentation of cholinergic neurotransmission, but the specific compounds and binding mechanisms responsible for this activity remain uncharacterized.

Scientific Research

Scientific evidence for Diplopterys cabrerana is limited almost exclusively to a single in vitro phytochemical and bioactivity study, with no peer-reviewed clinical trials isolating this species from ayahuasca formulations. The available in vitro work characterized alkaloid content (DMT 0.17–1.75% dry weight, ~0.7% total alkaloids), identified catechin and apigenin derivatives in aqueous extracts, and tested enzymatic inhibitory activities across acetylcholinesterase, 5-lipoxygenase, xanthine oxidase, nitric oxide, and α-glucosidase assays; cytotoxicity was absent at 1000 µg/mL in SH-SY5Y cells. Broader ayahuasca research, which includes D. cabrerana as one of several admixture plants, involves observational studies and small clinical trials examining psychological, psychiatric, and neurological outcomes, but these cannot disaggregate effects attributable specifically to this vine from those of Banisteriopsis caapi or other admixtures. Overall, the evidence base is classified as preliminary, with no replicated in vitro findings, no animal pharmacological studies specific to D. cabrerana, and no human clinical data isolating its constituent compounds.

Clinical Summary

No clinical trials have been conducted on Diplopterys cabrerana as an isolated botanical ingredient. Ayahuasca trials incorporating D. cabrerana as an admixture have examined outcomes including depression scores, anxiety, PTSD symptoms, and neuroimaging measures, but consistent attribution of specific effects to this species versus other brew components is methodologically impossible given multi-ingredient formulations. The broader ayahuasca clinical literature includes small open-label trials and one or two controlled studies with sample sizes generally below 30 participants, reporting promising signals for treatment-resistant depression and addiction, but these lack the rigor to support efficacy conclusions for D. cabrerana specifically. Confidence in any clinical claim directly attributable to Chaliponga is very low, and all bioactivity data should be considered hypothesis-generating pending dedicated pharmacological and clinical investigation.

Nutritional Profile

Diplopterys cabrerana has not been characterized for conventional macronutrient or micronutrient content, and it is not consumed as a food source. Phytochemical profiling of aqueous leaf extracts has identified N,N-dimethyltryptamine (DMT) at 0.17–1.75% dry weight as the primary alkaloid, with trace quantities of 5-MeO-DMT, bufotenin, N-methyltetrahydro-β-carboline, and methyltryptamine contributing to an approximately 0.7% total alkaloid fraction. Non-alkaloid constituents include catechin derivatives and apigenin derivatives, which are flavonoid-class polyphenols with documented antioxidant properties, alongside at least one uncharacterized tryptamine derivative; exact concentrations of these phenolic constituents have not been quantified in available literature. Bioavailability of DMT is near zero via oral route without MAO inhibition; the bioavailability and systemic absorption of the phenolic fraction from traditional decoctions has not been studied.

Preparation & Dosage

- **Traditional Ayahuasca Decoction**: Leaves and stems of D. cabrerana are combined with Banisteriopsis caapi vine segments and boiled in water for 4–12 hours, with multiple reduction cycles, to produce a concentrated tea; no standardized dose has been established and preparation varies significantly by tradition and practitioner.
- **Leaf Quantity in Traditional Use**: Indigenous and neo-shamanic practitioners typically use approximately 50–150 g of fresh D. cabrerana leaves per person per ceremony, though this varies widely and is not scientifically validated.
- **DMT Content Consideration**: Given leaf DMT concentrations of 0.17–1.75% dry weight, the psychoactive alkaloid load per serving is highly variable and dependent on plant chemotype, preparation technique, and co-administered MAOI content.
- **Oral Bioavailability Requirement**: DMT from D. cabrerana is orally inactive without concurrent MAO inhibition; effective systemic delivery requires co-administration with β-carboline-containing plants (e.g., Banisteriopsis caapi providing harmine, harmaline, tetrahydroharmine).
- **No Standardized Supplement Form**: Chaliponga is not available as a standardized extract, capsule, or tincture through legitimate supplement channels; dried leaf material circulates in some markets but lacks quality control, standardization, or established dosing guidance.
- **Research Context Dosing**: In the sole published in vitro study, bioactivities were observed at aqueous extract concentrations of 1.953–250 µg/mL, which have no direct translational dose equivalence to human supplemental use.

Synergy & Pairings

The defining synergistic pairing is with Banisteriopsis caapi, whose β-carboline alkaloids harmine, harmaline, and tetrahydroharmine inhibit monoamine oxidase A, thereby preventing first-pass DMT metabolism and enabling oral psychoactivity; without this combination, DMT from D. cabrerana is pharmacologically inert by the oral route. Emerging ethnobotanical and clinical interest also notes that ayahuasca formulations sometimes include Psychotria viridis as an alternative or complementary DMT source alongside D. cabrerana, potentially modulating alkaloid ratios and experiential character, though comparative pharmacokinetic data are absent. The flavonoid constituents (catechins, apigenin derivatives) identified in D. cabrerana extracts may theoretically exhibit additive antioxidant and anti-inflammatory effects when combined with other polyphenol-rich botanicals, but no synergy studies have been conducted.

Safety & Interactions

Diplopterys cabrerana lacks dedicated human toxicological data; in vitro cytotoxicity was absent in SH-SY5Y neuroblastoma cells at concentrations up to 1000 µg/mL aqueous extract, but this cannot be extrapolated to in vivo safety at psychoactive doses. The most clinically significant safety concerns arise from its entheogenic use in ayahuasca, where DMT-mediated serotonergic stimulation at 5-HT2A and other receptors creates risk of serotonin syndrome when combined with serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, tricyclic antidepressants, triptans, lithium, linezolid, or tramadol; this interaction is potentially life-threatening. The MAO-inhibiting β-carbolines present in traditional ayahuasca co-preparations also contraindicate consumption of tyramine-rich foods (aged cheeses, cured meats, fermented products) and sympathomimetic drugs due to risk of hypertensive crisis. Use during pregnancy or lactation is contraindicated given the known teratogenic potential of DMT-class alkaloids in animal models, the absence of human safety data, and the profound cardiovascular and psychological stress of the entheogenic experience; no maximum safe dose has been established for any population.